10 research outputs found
Nanotechnology against the novel coronavirus (severe acute respiratory syndrome coronavirus 2): Diagnosis, treatment, therapy and future perspectives
COVID-19, as an emerging infectious disease, has caused significant mortality and morbidity along with socioeconomic impact. No effective treatment or vaccine has been approved yet for this pandemic disease. Cutting-edge tools, especially nanotechnology, should be strongly considered to tackle this virus. This review aims to propose several strategies to design and fabricate effective diagnostic and therapeutic agents against COVID-19 by the aid of nanotechnology. Polymeric, inorganic self-assembling materials and peptide-based nanoparticles are promising tools for battling COVID-19 as well as its rapid diagnosis. This review summarizes all of the exciting advances nanomaterials are making toward COVID-19 prevention, diagnosis and therapy
CuFe<sub>2</sub>O<sub>4</sub> decorated with BSA as a potential nanoradioenhancer for enhanced X-ray radiation therapy of brain tumor
Glioblastoma (GBM) is a type of the central nervous system malignancy and considered as the most lethal and aggressive primary brain tumor. Adjuvant radiotherapy (RT) along with temozolomide (TMZ) is considered as the standard treatment regimen for GBM. However, implementation of RT in tumor suppression is frequently accompanied by several side effects. Additionally, dose limitation and radioresistance are other major drawbacks associated with radiation therapy. To this end, nanoradioenhancer/or nanoradiosensitizer based on high-Z metallic elements has emerged as a powerful treatment modality in GBM therapy. In this study, CuFe2O4 decorated with BSA nanoplatforms (CuFe2O4 @BSA) was fabricated to improve the theraputics potential of RT through sensitizing the U-87 GBM cells to X-ray radiation. The characterization techniques such as FTIR, XRD, EDS and UV-Vis spectroscopy confirmed successful fabrication of CuFe2O4 @BSA radioenhancer, while also TEM images indicated the prepared nanoradiosensitizers are uniform, homogenous, and spherical with an average size of about 5 nm. In vitro hemocompatibility and cytocompatibility of developed CuFe2O4 @BSA nanoradiosensitizers were also investigated by hemolysis and MTT assay, respectively. The merits of CuFe2O4 @BSA nanoplatforms in sensitizing the U-87 cells to the ionizing radiation were also exploited using intracellular ROS generation and MTT assay. It was found that CuFe2O4 @BSA nanoradiosensitizers did not cause any deleterious effects on primary human umbilical vein endothelial cells (HUVEC) of which the cell viability of all treated group was beyond 95%, endorsing the cytocompatibility and safety of these nanoplatforms for further assessment. Hemolysis assay also confirms the biosafety of CuFe2O4 @BSA nanoradiosensitizers, exhibiting no significant toxicity against human red blood cells in which the degree of hemolysis was less than 4%. In vitro cancer radiotherapy also demonstrated that the cell viability of U-87 GBM was considerably decreased once co-modality of X-ray and CuFe2O4 @BSA nanoradiosensitizers were used simultaneously. Radiosensitizing ability of these nanoparticles was also proved by intracellular ROS generation, of which implementation of CuFe2O4@BSA nanoradiosensitizers upon X-ray irradiation resulted in superior ROS production. Overall, these findings provide vital evidence for applicability of prepared CuFe2O4 @BSA nanoradiosensitizers in killing the primary brain tumor cells specifically GBM
CuFe2O4 decorated with BSA as a potential nanoradioenhancer for enhanced X-ray radiation therapy of brain tumor
Glioblastoma (GBM) is a type of the central nervous system malignancy and considered as the most lethal and aggressive primary brain tumor. Adjuvant radiotherapy (RT) along with temozolomide (TMZ) is considered as the standard treatment regimen for GBM. However, implementation of RT in tumor suppression is frequently accompanied by several side effects. Additionally, dose limitation and radioresistance are other major drawbacks associated with radiation therapy. To this end, nanoradioenhancer/or nanoradiosensitizer based on high-Z metallic elements has emerged as a powerful treatment modality in GBM therapy. In this study, CuFe2O4 decorated with BSA nanoplatforms (CuFe2O4 @BSA) was fabricated to improve the theraputics potential of RT through sensitizing the U-87 GBM cells to X-ray radiation. The characterization techniques such as FTIR, XRD, EDS and UV–Vis spectroscopy confirmed successful fabrication of CuFe2O4 @BSA radioenhancer, while also TEM images indicated the prepared nanoradiosensitizers are uniform, homogenous, and spherical with an average size of about 5 nm. In vitro hemocompatibility and cytocompatibility of developed CuFe2O4 @BSA nanoradiosensitizers were also investigated by hemolysis and MTT assay, respectively. The merits of CuFe2O4 @BSA nanoplatforms in sensitizing the U-87 cells to the ionizing radiation were also exploited using intracellular ROS generation and MTT assay. It was found that CuFe2O4 @BSA nanoradiosensitizers did not cause any deleterious effects on primary human umbilical vein endothelial cells (HUVEC) of which the cell viability of all treated group was beyond 95%, endorsing the cytocompatibility and safety of these nanoplatforms for further assessment. Hemolysis assay also confirms the biosafety of CuFe2O4 @BSA nanoradiosensitizers, exhibiting no significant toxicity against human red blood cells in which the degree of hemolysis was less than 4%. In vitro cancer radiotherapy also demonstrated that the cell viability of U-87 GBM was considerably decreased once co-modality of X-ray and CuFe2O4 @BSA nanoradiosensitizers were used simultaneously. Radiosensitizing ability of these nanoparticles was also proved by intracellular ROS generation, of which implementation of CuFe2O4 @BSA nanoradiosensitizers upon X-ray irradiation resulted in superior ROS production. Overall, these findings provide vital evidence for applicability of prepared CuFe2O4 @BSA nanoradiosensitizers in killing the primary brain tumor cells specifically GBM
Preparation of alginate coated Pt nanoparticle for radiosensitization of breast cancer tumor
© 2023Noble metals as high atomic number elements can localize X-ray radiation within tumor cells by exploiting different mechanisms. Here, alginate (Alg)-coated platinum nanoparticles (Pt@Alg) were synthesized, characterized, and implemented as a radiosensitizer to enhance X-ray therapeutic efficacy in breast cancer in vitro and in vivo. Alg not only improves the biocompatibility of the radioenhancer, but also stabilizes the nanoparticles. Pt@Alg was studied by different characterization methods including DLS, STEM, Fe-SEM, XRD, XPS, FT-IR and UV–Vis spectrophotometry. The nanosystem provided a higher level of intracellular ROS in malignant cells and enhanced cancer cell death under X-Ray irradiation. Clonogenic assay also demonstrated the radiosensitizing properties of the nanosystem, in vitro. In vivo result show tumor growth restraining properties of the nanosystem when it was administrated along with X-Ray irradiation. Histopathology results confirmed the impact of nanosystem and X-ray co-treatment, as well. Altogether, the importance of radiosensitizers for improving radiotherapy outcomes was highlighted
Preparation, characterization, and evaluation of amino acid modified magnetic nanoparticles: drug delivery and MRI contrast agent applications
Chemoradiation therapy of 4T1 cancer cells with methotrexate conjugated platinum nanoparticles under X-Ray irradiation
© 2023 Elsevier B.V.Bovine serum albumin (BSA) coated platinum (Pt) nanoparticles (Pt@BSA NPs) were synthesized, followed by the conjugation of an anticancer drug (MTX) with the aim of chemoradiation therapy. The physical and chemical properties of Pt@BSA-MTX were evaluated by DLS, FESEM, STEM, UV–Vis and XRD. A release study was performed in the presence and absence of the proteinase K enzyme. In terms of morphology, nanoparticles appeared to be monodispersed and spherical. The size of nanoparticles was 7.4 ± 1.4 nm. Release behavior of Pt@BSA-MTX depended significantly on enzyme presence which accelerated and promoted the release of MTX. The improved chemoradiation was demonstrated in vitro using MTT, colony formation and apoptosis assays on mouse breast carcinoma cells (4T1). It was concluded that the combination of a nanoradiosensitizer with a chemotherapeutic agent resulted in superior anticancer activity after X-ray exposure
Targeted CuFe2O4 hybrid nanoradiosensitizers for synchronous chemoradiotherapy
© 2022 Elsevier B.V.Multifunctional nanoplatforms based on novel bimetallic nanoparticles have emerged as effective radiosensitizers owing to their potential capability in cancer cells radiosensitization. Implementation of chemotherapy along with radiotherapy, known as synchronous chemoradiotherapy, can augment the treatment efficacy. Herein, a tumor targeted nanoradiosensitizer with synchronous chemoradiotion properties, termed as CuFe2O4@BSA-FA-CUR, loaded with curcumin (CUR) and modified by bovine serum albumin (BSA) and folic acid (FA) was developed to enhance tumor accumulation and promote the anti-cancer activity while attenuating adverse effects. Both copper (Cu) and iron (Fe) were utilized in the construction of these submicron scale entities, therefore strong radiosensitization effect is anticipated by implementation of these two metals. The structure–function relationships between constituents of nanomaterials and their function led to the development of nanoscale materials with great radiosensitizing capacity and biosafety. BSA was used to anchor Fe and Cu ions but also to improve colloidal stability, blood circulation time, biocompatibility, and further functionalization. Moreover, to specifically target tumor sites and enhance cellular uptake, FA was conjugated onto the surface of hybrid bimetallic nanoparticles. Finally, CUR as a natural chemotherapeutic agent was encapsulated into the developed bimetallic nanoparticles. With incorporation of all abovementioned stages into one multifunctional nanoplatform, CuFe2O4@BSA-FA-CUR is produced for synergistic chemoradiotherapy with positive outcomes. In vitro investigation revealed that these nanoplatforms bear excellent biosafety, great tumor cell killing ability and radiosensitizing capacity. In addition, high cancer-suppression efficiency was observed through in vivo studies. It is worth mentioning that co-use of CuFe2O4@BSA-FA-CUR nanoplatforms and X-ray radiation led to complete tumor ablation in almost all of the treated mice. No mortality or radiation-induced normal tissue toxicity were observed following administration of CuFe2O4@BSA-FA-CUR nanoparticles which highlights the biosafety of these submicron scale entities. These results offer powerful evidence for the potential capability of CuFe2O4@BSA-FA-CUR in radiosensitization of malignant tumors and opens up a new avenue of research in this area
Magnetite and bismuth sulfide Janus heterostructures as radiosensitizers for in vivo enhanced radiotherapy in breast cancer
Janus heterostructures based on bimetallic nanoparticles have emerged as effective radiosensitizers owing to their radiosensitization capabilities in cancer cells. In this context, this study aims at developing a novel bime-tallic nanoradiosensitizer, Bi2S3-Fe3O4, to enhance tumor accumulation and promote radiation-induced DNA damage while reducing adverse effects. Due to the presence of both iron oxide and bismuth sulfide metallic nanoparticles in these newly developed nanoparticle, strong radiosensitizing capacity is anticipated through the generation of reactive oxygen species (ROS) to induce DNA damage under X-Ray irradiation. To improve blood circulation time, biocompatibility, colloidal stability, and tuning surface functionalization, the surface of Bi2S3-Fe3O4 bimetallic nanoparticles was coated with bovine serum albumin (BSA). Moreover, to achieve higher cellular uptake and efficient tumor site specificity, folic acid (FA) as a targeting moiety was conjugated onto the bimetallic nanoparticles, termed Bi2S3@BSA-Fe3O4-FA. Biocompatibility, safety, radiation-induced DNA damage by ROS activation and generation, and radiosensitizing ability were confirmed via in vitro and in vivo assays. The administration of Bi2S3@BSA-Fe3O4-FA in 4T1 breast cancer murine model upon X-ray radiation revealed highly effective tumor eradication without causing any mortality or severe toxicity in healthy tissues. These findings offer compelling evidence for the potential capability of Bi2S3@BSA-Fe3O4-FA as an ideal nanoparticle for radiation-induced cancer therapy and open interesting avenues of future research in this area
Recommended from our members
Nanotechnology against the novel coronavirus (severe acute respiratory syndrome coronavirus 2): diagnosis, treatment, therapy and future perspectives
Coronavirus 2019 (COVID-19), as an emerging infectious disease, has caused significant mortality and morbidity along with socioeconomic impact. No effective treatment or vaccine has been approved yet for this pandemic disease. Cutting-edge tools, especially nanotechnology, should be strongly considered to tackle this virus. This review aims to propose several strategies to design and fabricate effective diagnostic and therapeutic agents against COVID-19 by the aid of nanotechnology. Polymeric, inorganic self-assembling materials and peptide-based nanoparticles are promising tools for battling COVID-19 as well as its rapid diagnosis. This review summarizes all of the exciting advances nanomaterials are making toward COVID-19 prevention, diagnosis and therapy